Summarized by Masters of Longevity from PR Newswire.
Innogen granted Arcera exclusive rights to efsubaglutide alfa in select regions.

Key Takeaways
- Arcera obtained exclusive rights in Africa, Latin America, Middle East.
- Innogen will receive US$38 million upfront and near-term milestones.
- Clinical studies showed weight loss and HbA1c reductions in trials.



